• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.71% Nasdaq Down1.22%

    More On PVTTF

    Quotes

    Charts

    News & Info

    Company

    Analyst Coverage

    • Analyst Opinion
    • Analyst Estimates

    Ownership

    • Major Holders
    • Insider Transactions
    • Insider Roster

    Financials


    Pivotal Therapeutics Inc. (PVTTF)

    -Other OTC
    0.05 0.00(0.00%) Jun 16
    Add to Portfolio
    ProfileGet Profile for:
    Pivotal Therapeutics Inc.
    81 Zenway Boulevard
    Unit 10
    Woodbridge, ON L4H 0S5
    Canada - Map
    Phone: 905-856-9797
    Fax: 905-856-2177
    Website: http://www.pivotaltherapeutics.us

    Details 
    Index Membership:N/A
    Sector:N/A
    Industry:N/A
    Full Time Employees:N/A

    Business Summary 

    Pivotal Therapeutics Inc., a specialty pharmaceutical company, focuses on the treatment of cardiovascular diseases and overall health. Its lead product, VASCAZEN, is a prescription only medical food formulated for clinical dietary management of cardiovascular disease in patients with documented coronary heart disease and who are deficient in blood Omega-3 fatty acids, eicosapentaenoic acid, and docosahexanenoic acid levels. The company also offers OMAZEN for the maintenance of good health through elevating Omega-3 fatty acid levels. In addition, the company develops Benefishial product line for overall health, cardiovascular health, prenatal health, toddler’s health, child’s health, and pet’s health. Further, it is developing PVT-100 indicated for the stabilization of vulnerable plaque in patients undergoing carotid endarterectomy. Pivotal Therapeutics Inc. sells VASCAZEN in the United States and OMAZEN in Canada. The company is headquartered in Woodbridge, Canada.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Pivotal Therapeutics Inc.

    Key Executives 
     PayExercised
    Mr. Eugenio Gregorio Bortoluzzi B.Com., MBA,
    Co-Founder, Chief Exec. Officer, Chief Financial Officer, Director, Member of Corp. Governance Committee and Member of Disclosure Committee
    243.00K0.00
    Mrs. Rachelle MacSweeney B.Sc., MBA,
    Co-Founder, Pres, Chief Operating Officer, Director, Member of Fin.Audit Committee, Member of Corp. Governance Committee and Member of Disclosure Committee
    255.00K0.00
    Dr. George Jackowski Ph.D., 64
    Co-Founder, Chief Scientific Officer, Director and Member of Compensation Committee
    291.00K0.00
    Dr. Jason Yantha Ph.D.,
    Director of Scientific Operations & Medical Communications
    N/AN/A
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.